Anzeige
Mehr »
Freitag, 15.08.2025 - Börsentäglich über 12.000 News
Neue Bohrergebnisse, Sichtgold und eine 7-fache Bewertungslücke, die zu groß ist, um sie zu ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
814 Leser
Artikel bewerten:
(2)

Clever Leaves Granted European Union Good Manufacturing Practices (EU GMP) Certification

Clever Leaves' Colombian operation is the first medical cannabis facility to receive EU GMP certification in Latin America

NEW YORK, July 09, 2020 (GLOBE NEWSWIRE) -- Clever Leaves (the "Company"), a leading multi-national operator (MNO) and licensed producer of pharmaceutical-grade medical cannabis and hemp extracts, has been granted European Union Good Manufacturing Practices (EU GMP) certification by the Croatian Agency for Medicinal Products and Medical Devices (HALMED) for its pharmaceutical post-harvest facility and laboratory located outside Bogota, Colombia, to produce Active Pharmaceutical Ingredients (API), semi-finished and finished cannabis products for medical purposes.

The certification recognizes that Clever Leaves' production facilities comply with quality standards and production guidelines required by the EU for the manufacturing of cannabis and hemp-based pharmaceutical products. EU GMP certification is generally required to import medical cannabis products into the European Union and is expected to broaden Clever Leaves' ability to serve international markets.

"EU GMP certification greatly expands Clever Leaves' ability to serve the burgeoning European medical cannabis and hemp markets, which have very strict quality, compliance and regulatory requirements. EU GMP certification expands an early mover advantage for Clever Leaves in the pharmaceutical channel as global demand increases and more legal cannabis geographies emerge," said Kyle Detwiler, CEO of Clever Leaves.

"As the first company in Latin America and one of a few medical cannabis companies in the world with EU GMP certification, this is a major accomplishment for our operations, regulatory, and quality control teams, and speaks to our commitment to provide our clients and patients with high quality and consistent, pharmaceutical grade products," said Andres Fajardo, President of Clever Leaves.

Clever Leaves is a global leader in low-cost, high quality and large-scale cannabinoid production. The Company is one of the world's largest medical cannabis operations in terms of capacity, boasting 1.8 million sq. ft of current cultivation capacity in Colombia and 108,000 kg/year of extraction capacity as well as a pre-licensed cultivation operation in Portugal. Clever Leaves is also pleased to announce that to date the Company has exported products to Australia, Brazil, Canada, Germany, Great Britain, Poland and the United States, among others.

Clever Leaves has achieved several significant milestones including becoming the first and only Colombian cannabis company to be GMP certified by INVIMA, the Colombian food and drug agency, as well as the first to receive Good Agricultural and Collecting Practices (GACP) certification in the Americas by the Control Union's Medical Cannabis Standard (CUMCS).

About Clever Leaves

Clever Leaves is a multi-national cannabis company with a mission to operate in compliance with federal and state laws and with an emphasis on ecologically sustainable, large-scale cultivation and processing as the cornerstones of its global cannabis business. Clever Leaves is a leading vertically integrated producer of medical cannabis and hemp extracts and is currently cultivating over 1.8 million square feet of greenhouses under Good Agricultural and Collection Practices (GACP) in Colombia. Clever Leaves' Colombian operation maintains European Union Good Manufacturing Practices (EU GMP) certification as well as Good Manufacturing Practices certification from INVIMA, Colombia's food and drug regulatory agency. Clever Leaves' first extraction facility is currently capable of extracting more than 100.000 kilograms of dried flower per year. In November 2019, Clever Leaves received a pre-license notice and authorization from INFARMED I.P., the Portuguese pharmaceutical regulatory authority, to start preliminary cultivation operations for R&D purposes in Portugal. Based on this authorization, Clever Leaves Portugal was able to cultivate medicinal cannabis for research and development purposes on its 85-hectare farm. Clever Leaves is one of the world's largest hemp and medical cannabis producers, with a global footprint encompassing brands, extraction facilities, cultivation operations and other investments across Canada, Colombia, Germany, Portugal, and the United States.

Press contacts:
McKenna Miller
KCSA Strategic Communications
+1347-487-6197
mmiller@kcsa.com

Diana Sigüenza
Strategic Communications Director
+573102368830
Diana.siguenza@cleverleaves.com

© 2020 GlobeNewswire (Europe)
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.